Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.
暂无分享,去创建一个
E. Montgomery | J. Eshleman | A. Maitra | M. Canto | Hong Ding | K. Yong | P. Prasad | Gaixia Xu | H. Alvarez | Jean S. Wang | P. Rojas
[1] F. Sato,et al. Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. , 2008, Cancer research.
[2] S. Skates,et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. , 2007, Chest.
[3] Richard G. Moore,et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. , 2007, Gynecologic oncology.
[4] T. Wu,et al. Control of human mesothelin-expressing tumors by DNA vaccines , 2007, Gene Therapy.
[5] W. Ma,et al. A phase 1 study of MORAb-009, a monoclonal antibody against mesothelin in pancreatic cancer, mesothelioma and ovarian adenocarcinoma , 2007 .
[6] Sailing He,et al. Imaging pancreatic cancer using surface-functionalized quantum dots. , 2007, The journal of physical chemistry. B.
[7] Tammy F. Glenn,et al. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration , 2007, International journal of cancer.
[8] Sailing He,et al. Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells. , 2007, Nano letters.
[9] T. Wu,et al. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. , 2007, Vaccine.
[10] Chien-Nan Lee,et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. , 2006, Anticancer research.
[11] S. Batra,et al. Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. , 2006, American journal of clinical pathology.
[12] N. Sardesai,et al. Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker , 2006, Cancer Epidemiology Biomarkers & Prevention.
[13] N. Ordóñez,et al. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study , 2006, Modern Pathology.
[14] E. Montgomery,et al. Overexpression of Claudin Proteins in Esophageal Adenocarcinoma and Its Precursor Lesions , 2006, Applied immunohistochemistry & molecular morphology : AIMM.
[15] I. Eltoum,et al. Use of mesothelin as a marker for mesothelial cells in cytologic specimens. , 2006, Seminars in diagnostic pathology.
[16] C. Mamot,et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.
[17] M. Lerner,et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. , 2005, American journal of clinical pathology.
[18] E. Montgomery,et al. Concordant Loss of MTAP and p16/CDKN2A Expression in Gastroesophageal Carcinogenesis: Evidence of Homozygous Deletion in Esophageal Noninvasive Precursor Lesions and Therapeutic Implications , 2005, The American journal of surgical pathology.
[19] R. Hruban,et al. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways , 2005, Modern Pathology.
[20] R. Odze,et al. Immunohistochemistry Can Help Distinguish Metastatic Pancreatic Adenocarcinomas From Bile Duct Adenomas and Hamartomas of the Liver , 2005, The American journal of surgical pathology.
[21] E. Montgomery,et al. CDC2/CDK1 Expression in Esophageal Adenocarcinoma and Precursor Lesions Serves as a Diagnostic and Cancer Progression Marker and Potential Novel Drug Target , 2005, The American journal of surgical pathology.
[22] R. Hruban,et al. Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.
[23] S. Nie,et al. In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.
[24] Janusz Jankowski,et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. , 2004, Gastroenterology.
[25] B. Reid,et al. Focus on Barrett's esophagus and esophageal adenocarcinoma. , 2004, Cancer cell.
[26] I. Pastan,et al. Mesothelin , 2004, Clinical Cancer Research.
[27] J. Cameron,et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. , 2004, Human pathology.
[28] Christine A Iacobuzio-Donahue,et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. , 2003, Cancer research.
[29] Trevor Hastie,et al. Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.
[30] N. Ordóñez,et al. Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.
[31] D. Faigel,et al. Novel Markers of Pancreatic Adenocarcinoma in Fine-Needle Aspiration: Mesothelin and Prostate Stem Cell Antigen Labeling Increases Accuracy in Cytologically Borderline Cases , 2003, Applied immunohistochemistry & molecular morphology : AIMM.
[32] J. Cameron,et al. Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray , 2003, Modern Pathology.
[33] I. Pastan,et al. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. , 2002, Molecular cancer therapeutics.
[34] L. Brown,et al. Epidemiologic trends in esophageal and gastric cancer in the United States. , 2002, Surgical oncology clinics of North America.
[35] S. Spechler,et al. Clinical practice. Barrett's Esophagus. , 2002, The New England journal of medicine.
[36] J. Cameron,et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] E. Montgomery,et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. , 2001, Human pathology.
[38] G. Riggins,et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. , 2000, Cancer research.
[39] Prateek Sharma,et al. Long-term follow-up of Barrett's high-grade dysplasia , 2000, American Journal of Gastroenterology.
[40] I. Pastan,et al. Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma , 2000, Journal of immunotherapy.
[41] D. Antonioli,et al. Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma. , 1997, Gastroenterology clinics of North America.
[42] I. Pastan,et al. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[43] I. Pastan,et al. Molecular cloning and expression of a cDNA encoding a protein detected by the ki antibody from an ovarian carcinoma (OVCAR‐3) cell line , 1994, International journal of cancer.
[44] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[45] R. Hruban,et al. Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor. , 2006, Cancer detection and prevention.
[46] W. Pardridge. Gene targeting in vivo with pegylated immunoliposomes. , 2003, Methods in enzymology.